Market research
WVE Wave Life Sciences Ltd
NASDAQ USD Healthcare
Latest close
As of 29 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 625M
- P/E ratio
- Not available
- Analyst target
- 17.2185
- Dividend yield
- Not available
- Beta
- -1.43
Profile
Instrument facts
- Exchange
- NASDAQ
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
- ISIN
- Not available
- Market cap
- 625M
- P/E ratio
- Not available
- Analyst target
- 17.2185
- Dividend yield
- Not available
- Beta
- -1.43
About
About Wave Life Sciences Ltd
Wave Life Sciences, Inc., a clinical-stage biotechnology company, focuses on unlocking the potential of ribonucleic acid (RNA) medicines to transform human health. Its RNA medicines platform, PRISM, combines RNA medicine modalities, chemistry innovation, and deep insights in human genetics to deliver scientific breakthroughs that treat rare and common disorders. Its pipeline focuses on obesity (WVE-007), alpha-1 antitrypsin deficiency (AATD) (WVE-006), and PNPLA3 I148M liver disease (WVE-008) programs; and clinical programs for Duchenne muscular dystrophy and Huntington's disease, as well as various preclinical programs utilizing its RNA medicines platform. Wave Life Sciences, Inc. was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Research context
Wave Life Sciences Ltd appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Biotechnology
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the WVE discussion.
5 years, 6 months ago
Wave Life Sciences Ltd is currently in a long term downtrend where the price is trading 16.0% below its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.4.
Wave Life Sciences Ltd's total revenue rose by 293.3% to $9M since the same quarter in the previous year.
Its net income has increased by 49.3% to $-29M since the same quarter in the previous year.
Finally, its free cash flow grew by 48.9% to $-32M since the same quarter in the previous year.
Based on the above factors, Wave Life Sciences Ltd gets an overall score of 4/5.